AI-Powered Discovery Pipeline

Our technology extends to a wide range of complex diseases.

Oncology

Cancers are mosaics with inter- and intra-tumor heterogeneity, evolving clones, and microenvironmental effects; multi-omics unifies genomic, transcriptomic, proteomic, and spatial signals to reveal actionable subtypes and vulnerabilities.

Autoimmune

Diverse genetic risk, epigenetic priming, and tissue-specific immune circuits create overlapping phenotypes; multi-omics resolves endotypes and pathways to guide targeted, patient-specific immunomodulation.

Neurodegenerative

Nexomic’s AI-powered platform for biopharma and translational research teams, accelerating the development of targeted diagnostics and therapies. It transforms multi-omic data into explainable insights, enabling the discovery of novel biomarkers, therapeutic targets, and precise trial designs.

Cardiometabolic

Psychiatric

Oncology

Autoimmune

Neurodegenerative

Overlapping proteinopathies, cell-type–specific vulnerability, and progressive network failure drive heterogeneity; multi-omics (including single-cell/spatial) maps pathogenic pathways to stratify disease and prioritize interventions

Cardiometabolic

Gene–environment interactions across liver, muscle, adipose, heart, and microbiome yield mixed phenotypes; multi-omics links variants to pathways and traits to sharpen risk stratification and therapeutic choice

Psychiatric

Polygenic architecture, developmental trajectories, and brain–immune–metabolic crosstalk blunt single biomarkers; multi-omics integrates layers to uncover mechanistic subtypes and predictors of treatment response.